TeamDrive
RUS

Japan saved $12.2 billion through use of generics

12 March 2018

GMP News

Japan’s Ministry of Health, Labour and Welfare (MHLW) suggested that the country’s push to lower prescription costs by switching to generic drugs is forecast to have saved $12.2 billion in fiscal 2017.

The reduction is about 40 percent larger than the savings estimated for fiscal 2015. In 2015, the MHLW unveiled a plan to boost the competitiveness of the country’s pharmaceutical industry, with the government aiming to increase the share of generic drugs used to at least 80 percent by 2020, compared to 46.9 percent in 2013. According to the latest figures from the health ministry, as of the end of September 2017, the share of generic drugs was 65.8 percent.

The move to increase the use of generic drugs is one of a number of measures introduced in Japan to curb rising health care spending, with the government announcing at the end of 2016 plans to review drug prices annually instead of once every two years, with the review to include all prescription medicines.


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more